CombiMatrix Corp  

(Public, NASDAQ:CBMX)   Watch this stock  
Find more results for CBMX
2.80
-0.02 (-0.71%)
Real-time:   10:56AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.80 - 2.84
52 week 2.62 - 20.10
Open 2.83
Vol / Avg. 4,317.00/70,434.00
Mkt cap 6.56M
P/E     -
Div/yield     -
EPS -8.53
Shares 2.38M
Beta 0.28
Inst. own 8%
Nov 2, 2016
Q3 2016 CombiMatrix Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Sep 13, 2016
CombiMatrix Corp at Rodman & Renshaw Global Investment Conference
Aug 3, 2016
Q2 2016 CombiMatrix Corp Earnings Call
Aug 3, 2016
Q2 2016 CombiMatrix Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -39.75% -65.43%
Operating margin -39.46% -64.81%
EBITD margin - -60.90%
Return on average assets -47.27% -79.75%
Return on average equity -60.80% -118.05%
Employees 65 -
CDP Score - -

Address

310 Goddard Ste 150
IRVINE, CA 92618-4617
United States - Map
+1-949-7530624 (Phone)
+1-949-7531504 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

CombiMatrix Corporation is a provider of molecular diagnostic solutions. The Company specializes in pre-implantation genetic screening, miscarriage analysis, prenatal diagnosis and pediatric developmental disorders, offering deoxyribonucleic acid-based testing for the detection of genetic abnormalities, which cannot be identified through traditional methodologies. It performs genetic testing utilizing a range of cytogenomic techniques, including chromosomal microarray analysis, fluorescence in situ hybridization and karyotyping. Its prenatal and postnatal microarray focuses on diagnosing genomic syndromes associated with intellectual disability, developmental delays, congenital anomalies, dysmorphic features and autism spectrum disorders. It develops and markets its molecular testing services in approximately four markets, such as in vitro fertilization (IVF), miscarriage analysis (products of conception analysis), prenatal genetics and postnatal developmental disorders.

Officers and directors

Robert Judd Jessup Chairman of the Board
Age: 68
Bio & Compensation  - Reuters
Mark McDonough President, Chief Executive Officer, Director
Age: 46
Bio & Compensation  - Reuters
Scott R. Burell CPA Chief Financial Officer, Treasurer, Secretary
Age: 51
Bio & Compensation  - Reuters
Scott Gottlieb M.D. Independent Director
Age: 43
Bio & Compensation  - Reuters
Robert E. Hoffman Independent Director
Age: 50
Bio & Compensation  - Reuters
Jeremy M. Jones Independent Director
Age: 74
Bio & Compensation  - Reuters
Lale White Independent Director
Age: 60
Bio & Compensation  - Reuters